Top 10 Finalist Nurses Announced for Inaugural Aster Guardians Global Nursing Award
Aster Guardians Global Nursing Award has just announced its top 10 finalists hailing from across the world. These nurses have been selected from over 24,000 nurses who applied from over 184 countries, through a stringent review process run independently by Ernst & Young LLP, a Screening Jury and a Grand Jury. All applications were evaluated to create a shortlist of 181 which underwent further review to put forward 41 top applications. These 41 applications were then reviewed by the Grand Jury to announce the top 10 finalists. All applicant nurses were asked to submit their applications based on four areas of contribution: Leadership, Research/Innovation, Patient Care and Society/Community Service.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220411005418/en/
The top 10 finalists, who will now undergo further evaluation to claim the grand prize of USD 250,000, are: Anna Qabale Duba from Kenya; Dida Jirma Bulle from Kenya; Francis Michael Fernando from United Kingdom; Jasmine Mohammed Sharaf from United Arab Emirates; Julia Dorothy Downing from United Kingdom; Lincy Padicala Joseph from India, Manju Dhandapani from India; Matthew James Ball from Australia; Rachel Abraham Joseph from United States and Wais Mohammad Qarani from Afghanistan. To know more about the top 10 finalists, please visit: https://www.asterguardians.com/.
Speaking on the top 10 finalists and the upcoming award ceremony to be held on 12th May – International Nurses Day, at The Atlantis, Dubai, Dr. Azad Moopen, Founder Chairman and Managing Director of Aster DM Healthcare said, “With over 7000 nurses as the main pillar of our organization, we at Aster witness their commitment and compassion every single day. During this pandemic, their critical contribution with dedication and sacrifice, putting their own safety and lives at risk, was brought to the forefront globally. We thought that it is appropriate to institute a global level award for the nurses to recognize the members of this noble profession. With over 24,000 nurses who applied, we are overwhelmed by the response received from different parts of the world for the inaugural edition of Aster Guardians Global Nursing Award. It has been a hard task for the eminent Jury members to shortlist the top 10 extraordinary nurses from the large number of applicants. We wish the finalists nominated in the top 10 all the very best for the final evaluation process.”
While one winner will be awarded the grand prize of USD 250,000, the other nine finalists will receive a monetary award. The final round will consist of public voting for each of the nurses starting from 26th April and in-person interview with the Grand Jury members consisting of Mr. Howard Catton - Chief Executive Officer, International Council of Nurses, Switzerland; Prof. Sheila Tlou - Co-Chairperson, Global HIV Prevention Coalition and Ex - Minister of Health & Member of Parliament – Govt. of Botswana; Prof. James Buchan - Adjunct Professor, WHO Collaborating Centre for Nursing; Mr. Muralee Thummarukudy, Acting Head, Resilience to Disasters and Conflicts Global Support Branch, United Nations Environment Programme, Switzerland; and Dr. Carolyn Gomes, Executive Director, Caribbean Vulnerable Communities Coalition (CVC), Jamaica.
About Aster DM Healthcare
Aster DM Healthcare Limited is one of the largest private healthcare service providers operating in GCC and in India. With an inherent emphasis on clinical excellence, we are one of the few entities in the world with a strong presence across primary, secondary, tertiary, and quaternary healthcare through our 27 hospitals, 118 clinics, 323 pharmacies and 66 labs & patient experience centres in seven countries, including India. We have over 24,350 plus dedicated staff including 3,110 doctors and 7,063 nurses across the geographies that we are present in, delivering a simple yet strong promise to our different stakeholders: "We'll treat you well."
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220411005418/en/
Contact information
Lavanya Mandal
Head of PR and Internal Communications, +971528126577
Email: lavanya.mandal@asterdmhealthcare.com
Facebook: https://www.facebook.com/AsterGuardians
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Transition Industries Signs Strategic Agreements for the Pacifico Mexinol Project, the Largest Standalone Ultra-Low Carbon Chemical Production Facility in the World30.6.2025 21:30:00 EEST | Press release
Transition Industries LLC, a developer of world-scale, net-zero carbon emissions methanol and green hydrogen projects in North America, held a signing event for an Engineering, Procurement, and Construction (EPC) contract with the consortium of Samsung E&A Co., Ltd. (Samsung E&A), Grupo Samsung E&A Mexico, S.A. de C.V., and Techint Engineering and Construction for the Pacifico Mexinol project located in Ahome, Sinaloa, Mexico, which is contingent upon the fulfillment of customary conditions precedent and obtainment of all required approvals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250630940954/en/ MAIRE group’s technology division NextChem, through its subsidiary KT TECH SpA, also signed a Basic Engineering, Critical and Proprietary Equipment Supply Agreement with Samsung E&A in connection with its proprietary NX AdWinMethanol®Zero technology supply to the project. Transition Industries is jointly developing the Pacif
Westinghouse and ITER Sign a $180M Contract to Advance Nuclear Fusion30.6.2025 16:45:00 EEST | Press release
Westinghouse Electric Company and ITER signed a contract for $180 million for the assembly of the vacuum vessel for the fusion reactor. This is a key milestone in the construction of the ITER reactor, leading the way toward the use of fusion as a practical future source of reliable carbon-free energy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250630497810/en/ The ITER Tokamak pit with the two vacuum vessel sector modules installed. Westinghouse has participated in the fabrication of the sectors of the vacuum vessel, as part of the Fusion for Energy (F4E) Consortium with its partners Ansaldo Nucleare and Walter Tosto. Westinghouse will be responsible for completing the vacuum vessel which is ITER’s most critical component: a hermetically sealed, double-walled steel container that will house the fusion plasma. When all the vacuum vessel sectors are in place, Westinghouse will start the most intensive stage of ITER assembl
Monetate Acquires SiteSpect to Deliver AI-Native Personalization and Testing at Enterprise Scale30.6.2025 16:00:00 EEST | Press release
Monetate, the leading AI-driven personalization platform, today announced it has acquired SiteSpect, a leader in A/B testing, to drive next-generation digital experience optimization. This acquisition accelerates Monetate’s vision to deliver intelligent, intentional, and individualized experiences at scale, powered by agentic AI and backed by the industry’s most advanced, enterprise-grade infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250630514541/en/ The combination of Monetate’s real-time personalization and SiteSpect’s zero-flicker testing will yield an industry-first solution for enterprise-grade personalization, testing, and optimization. For the first time, global ecommerce and digital experience leaders can access unified client-side and server-side experimentation with full personalization capabilities in a single solution, designed for scalability and regulatory compliance. Monetate is now the only e
SS&C Blue Prism Recognized as a Gartner® Magic Quadrant™ RPA Leader for the Seventh Consecutive Year30.6.2025 16:00:00 EEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that SS&C Blue Prism has been recognized as a Leader in the 2025 Gartner Magic Quadrant for Robotic Process Automation (RPA). “We’re delighted SS&C Blue Prism has been named a Leader in the Gartner Magic Quadrant for Robotic Process Automation for the seventh year running,” said Bill Stone, CEO and Chairman of SS&C Technologies. “SS&C Blue Prism combines market-leading RPA and orchestration technologies with the latest artificial intelligence so organizations can tackle more complex tasks and dynamic business processes. We’ve scaled to more than 2,700 digital workers and AI agents across our own operations, resulting in over $200 million in annual savings. With SS&C leading the charge on deployment, customers can be confident in rolling out SS&C’s automation solutions securely, effectively, and responsibly.” More than 2,800 companies worldwide leverage SS&C Blue Prism for AI-powered automation, helping organizations delive
Takeda Announces U.S. FDA Approval of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content 130.6.2025 15:00:00 EEST | Press release
Takeda(TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved GAMMAGARD LIQUID ERC [immune globulin infusion (human)] with less than or equal to 2 µg/mL IgA in a 10% solution, the only ready-to-use liquid immunoglobulin (IG) therapy with low immunoglobulin A (IgA) content, as replacement therapy for people two years of age and older with primary immunodeficiency (PI). As a ready-to-use liquid, GAMMAGARD LIQUID ERC may help ease the administration burden for patients and their health care providers by eliminating the need for reconstitution and can be administered intravenously or subcutaneously.1 “The approval of GAMMAGARD LIQUID ERC reinforces our commitment to supporting individualized treatment approaches for people with primary immunodeficiency, including a therapeutic option that has the lowest IgA content of any ready-to-use liquid immunoglobulin therapy, and can be administered intravenously or subcutaneously,” said Kristina Allikmets, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom